Active Ingredient History
Nalbuphine is a semi-synthetic opioid agonist-antagonist used commercially as an analgesic under a variety of trade names, including Nubain and Manfine. Nalbuphine is an agonist at kappa opioid receptors and an antagonist at mu opioid receptors. Nalbuphine analgesic potency is essentially equivalent to that of morphine on a milligram basis up to a dosage of approximately 30 mg. The opioid antagonist activity of Nalbuphine is one-fourth as potent as nalorphine and 10 times that of pentazocine. Nalbuphine is indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Nalbuphine can also be used as a supplement to balanced anesthesia, for preoperative and postoperative analgesia, and for obstetrical analgesia during labor and delivery. The onset of action of Nalbuphine occurs within 2 to 3 minutes after intravenous administration, and in less than 15 minutes following subcutaneous or intramuscular injection. The plasma half-life of nalbuphine is 5 hours, and in clinical studies, the duration of analgesic activity has been reported to range from 3 to 6 hours. Like pure µ-opioids, the mixed agonist-antagonist opioid class of drugs can cause side effects with initial administration of the drug but which lessen over time (“tolerance”). This is particularly true for the side effects of nausea, sedation and cognitive symptoms. These side effects can in many instances be ameliorated or avoided at the time of drug initiation by titrating the drug from a tolerable starting dose up to the desired therapeutic dose. An important difference between nalbuphine and the pure mu-opioid analgesic drugs is the “ceiling effect” on respiration. Respiratory depression is a potentially fatal side effect from the use of pure mu opioids. Nalbuphine has limited ability to depress respiratory function. NCATS
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Ablation Techniques (Phase 4)
Acute Pain (Phase 4)
Allergy and Immunology (Phase 4)
Analgesia (Phase 4)
Anemia, Sickle Cell (Phase 3)
Anesthesia (Phase 4)
Anesthesia, Epidural (Phase 2)
Anxiety (Phase 4)
Arthropathy, Neurogenic (Phase 4)
Bariatric Surgery (Phase 2/Phase 3)
Cesarean Section (Phase 4)
Cholecystitis (Phase 2/Phase 3)
Chronic Pain (Phase 2/Phase 3)
Cleft Palate (Phase 3)
Common Cold (Phase 1)
Conscious Sedation (Phase 2)
Cough (Phase 2)
Drugs, Investigational (Phase 4)
Emergence Delirium (Phase 1/Phase 2)
Fever (Phase 1)
Headache (Phase 1)
Health (Phase 1)
Healthy Volunteers (Phase 1)
Hemostatic Disorders (Phase 4)
Idiopathic Pulmonary Fibrosis (Phase 2)
Injection Site Reaction (Phase 4)
Intestinal Neoplasms (Phase 3)
Labor Pain (Phase 2)
Leukemia (Phase 3)
Leukemia, Lymphoid (Phase 4)
Leukemia, Myeloid, Acute (Phase 3)
Limb Deformities, Congenital (Phase 4)
Liver Diseases (Phase 1)
Lung Diseases (Phase 4)
Nalbuphine (Phase 2)
Obesity (Phase 2/Phase 3)
Opioid-Related Disorders (Phase 1)
Pain ()
Pain, Postoperative (Phase 4)
Patient Satisfaction (Phase 4)
Pharmacokinetics (Phase 4)
Pharyngitis (Phase 1)
Postoperative Complications (Phase 2)
Postoperative Nausea and Vomiting (Phase 4)
Prurigo (Phase 2/Phase 3)
Pruritus (Phase 3)
Quality of Life (Phase 2/Phase 3)
Respiratory Distress Syndrome (Phase 4)
Rhinorrhea (Phase 1)
Rotator Cuff Injuries (Phase 2)
Safety (Phase 4)
Sleep Apnea, Obstructive (Phase 4)
Sneezing (Phase 1)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
